JP2007504280A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504280A5
JP2007504280A5 JP2006532897A JP2006532897A JP2007504280A5 JP 2007504280 A5 JP2007504280 A5 JP 2007504280A5 JP 2006532897 A JP2006532897 A JP 2006532897A JP 2006532897 A JP2006532897 A JP 2006532897A JP 2007504280 A5 JP2007504280 A5 JP 2007504280A5
Authority
JP
Japan
Prior art keywords
antibody
ovr110
cells
cancer
pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006532897A
Other languages
English (en)
Japanese (ja)
Other versions
JP4884224B2 (ja
JP2007504280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/014490 external-priority patent/WO2004101756A2/en
Publication of JP2007504280A publication Critical patent/JP2007504280A/ja
Publication of JP2007504280A5 publication Critical patent/JP2007504280A5/ja
Application granted granted Critical
Publication of JP4884224B2 publication Critical patent/JP4884224B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006532897A 2003-05-09 2004-05-10 Ｏｖｒ１１０抗体組成物および使用方法 Expired - Fee Related JP4884224B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46955503P 2003-05-09 2003-05-09
US60/469,555 2003-05-09
US55295904P 2004-03-12 2004-03-12
US60/552,959 2004-03-12
US55646404P 2004-03-25 2004-03-25
US60/556,464 2004-03-25
PCT/US2004/014490 WO2004101756A2 (en) 2003-05-09 2004-05-10 Ovr110 antibody compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2007504280A JP2007504280A (ja) 2007-03-01
JP2007504280A5 true JP2007504280A5 (cg-RX-API-DMAC7.html) 2007-11-22
JP4884224B2 JP4884224B2 (ja) 2012-02-29

Family

ID=33458763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532897A Expired - Fee Related JP4884224B2 (ja) 2003-05-09 2004-05-10 Ｏｖｒ１１０抗体組成物および使用方法

Country Status (9)

Country Link
US (2) US7619068B2 (cg-RX-API-DMAC7.html)
EP (1) EP1633784B1 (cg-RX-API-DMAC7.html)
JP (1) JP4884224B2 (cg-RX-API-DMAC7.html)
AT (1) ATE516047T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004239301B2 (cg-RX-API-DMAC7.html)
CA (1) CA2525899C (cg-RX-API-DMAC7.html)
DK (1) DK1633784T3 (cg-RX-API-DMAC7.html)
IL (1) IL171797A (cg-RX-API-DMAC7.html)
WO (1) WO2004101756A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737255B1 (en) * 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
EP1539218A4 (en) * 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
WO2004039394A1 (en) 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7619068B2 (en) * 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AU2005304462B2 (en) 2004-11-10 2011-03-10 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AU2004325035B2 (en) * 2004-11-12 2011-09-08 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
ATE462726T1 (de) * 2005-01-07 2010-04-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
EP3058955B1 (en) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
BRPI0620601A2 (pt) 2005-12-08 2011-11-16 Medarex Inc anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e
ES2748397T3 (es) * 2006-01-04 2020-03-16 Fujirebio Diagnostics Inc Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013004776A2 (pt) 2010-08-27 2017-09-19 Stem Centrx Inc moduladores de proteína notum e métodos de uso
CN103476429B (zh) 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 新型调节剂及使用方法
AU2011338425A1 (en) 2010-12-08 2013-05-02 Stemcentrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2756094B1 (en) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antibodies and their uses
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP3095797B1 (en) 2012-02-24 2020-05-20 AbbVie Stemcentrx LLC Anti dll3 antibodies and methods of use thereof
SG10201801444WA (en) 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
US11402388B2 (en) 2012-07-10 2022-08-02 Takeda Pharmaceutical Company Limited Anti-MIF immunohistochemistry
AU2013361231A1 (en) 2012-12-19 2015-06-04 Amplimmune, Inc. B7-H4 specific antibodies, and compositions and methods of use thereof
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2970474B1 (en) 2013-03-14 2017-12-20 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US9993566B2 (en) 2013-08-28 2018-06-12 Abbvie Stemcentrx Llc SEZ6 modulators and methods of use
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
CA2928671A1 (en) 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
MX375284B (es) 2014-04-30 2025-03-06 Pfizer Conjugados de anticuerpo-fármaco anti-proteína tirosina quinasa 7 (anti-ptk7).
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
TW201805309A (zh) 2016-04-21 2018-02-16 艾伯維史坦森特瑞斯有限責任公司 新穎抗－bmpr1b抗體及使用方法
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
TWI870011B (zh) 2017-08-25 2025-01-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
WO2019147670A1 (en) 2018-01-23 2019-08-01 Nextcure, Inc. B7-h4 antibodies and methods of use thereof
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CN116172059A (zh) * 2021-11-29 2023-05-30 内蒙古伊利实业集团股份有限公司 青苹果微胶囊、包含其的发酵乳及发酵乳饮料和制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences, Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1999063088A2 (en) 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US7737255B1 (en) * 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20050229272A1 (en) 1999-12-30 2005-10-13 Monica Driscoll Compositions and methods for gene silencing
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
MXPA02010011A (es) * 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
WO2002002624A2 (en) 2000-06-30 2002-01-10 Amgen, Inc. B7-like molecules and uses thereof
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7619068B2 (en) * 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2008067283A2 (en) * 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2007504280A5 (cg-RX-API-DMAC7.html)
Cheng et al. MORAb-202, an antibody–drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity
JP6491701B2 (ja) 新規モジュレーターと使用の方法
RU2627176C2 (ru) Новые модуляторы и способы их применения
JP2021151263A (ja) シアリル−Ｌｅｗｉｓ ａに対するヒト抗体をコードする核酸
JP2022106840A (ja) Ｂ細胞成熟抗原結合タンパク質
JP2010510809A5 (cg-RX-API-DMAC7.html)
Sokolowska-Wedzina et al. High-affinity internalizing human scFv-Fc antibody for targeting FGFR1-overexpressing lung cancer
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
CN109422811A (zh) 抗cd47抗体及其用途
CN111183156A (zh) 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法
JP2008546780A5 (cg-RX-API-DMAC7.html)
JP2012100677A5 (cg-RX-API-DMAC7.html)
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
US20120301394A1 (en) Targeting and in vivo imaging of tumor-associated macrophages
NZ283366A (en) Monoclonal antibodies recognizing tie receptors (receptor tyrosine kinase) and their use
RU2015108348A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2010537671A5 (cg-RX-API-DMAC7.html)
KR20140027051A (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
JP2017538439A5 (cg-RX-API-DMAC7.html)
CN109970856A (zh) 抗lag-3抗体及其用途
JP2008537673A5 (cg-RX-API-DMAC7.html)
JP2014515600A5 (cg-RX-API-DMAC7.html)
JP2011509246A5 (cg-RX-API-DMAC7.html)
JP2007516232A5 (cg-RX-API-DMAC7.html)